Compare Southern Copper Corp (SCCO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Sanofi SA — how do they compare? Southern Copper Corp trades at $209 (market cap $176.10B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Southern Copper Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SCCO | SNY | |
|---|---|---|
Market Cap | $176.10B | $104.06B |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $52.34 |
52-Week Low | $102.10 | $41.33 |
Enterprise Value | $177.39B | $124.09B |
Dividend Yield | 2.11% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $208.56, up 4.93% with strong bullish technical signals and positive earnings momentum. The company demonstrates robust fundamentals with 2025 revenue of $13.42B, net income margin of 35.87%, and consistent earnings beats. Recent news highlights copper's role in AI infrastructure demand, with SCCO benefiting from rising metal prices and a $20.5B investment plan for production growth.
SCCO presents growth potential from copper demand trends but trades at premium valuations (P/E 31.29) above analyst consensus target of $154.58. Key risks include production declines and execution challenges on expansion projects. Institutional buying activity suggests confidence in long-term prospects despite mixed analyst ratings.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
